Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03603431 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers | PHASE1 | COMPLETED | 42 | — | — | Apr 9, 2018 | Mar 13, 2019 | May 7, 2019 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Single Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Multiple Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Multiple Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Name | Type | Description |
|---|---|---|
| MRG-110 | DRUG | Single ascending doses of MRG-110 |
| Placebo | DRUG | Single doses of placebo |
Key Inclusion Criteria: * Normal healthy volunteers. * Females must be of non-childbearing potential. * If engaged in sexual relations with a female of child-bearing potential, males must be surgically sterile or must be willing to use a highly effective method of contraception throughout their stu...